THURSDAY, May 17, 2018 — Less appears to be more when it comes to treating epilepsy with the marijuana extract cannabidiol, a new clinical trial suggests.
Patients taking a 10-milligram daily dose of pharmaceutical grade cannabidiol, or CBD, experienced nearly as great a reduction in seizures as patients on 20 mg, and with fewer side effects, said lead researcher Dr. Orrin Devinsky. He is director of NYU Langone’s Comprehensive Epilepsy Center in New York City.
This is the third clinical trial to show that the cannabidiol medication Epidiolex is useful in treating two rare forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, Devinsky said.
An advisory panel for the U.S. Food and Drug Administration unanimously recommended in April that Epidiolex be approved for use in the United States. The FDA does not have to follow the recommendations of its advisory panels, but it typically does.